Holen Sie sich die Stockscreener-App
15.89
1.34%
0.21
Handel nachbörslich:
16.10
0.21
+1.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.68
Offen:
$16.46
24-Stunden-Volumen:
3.70M
Relative Volume:
1.13
Marktkapitalisierung:
$1.68B
Einnahmen:
$2.18B
Nettoeinkommen (Verlust:
$-64.32M
KGV:
-16.48
EPS:
-0.9641
Netto-Cashflow:
$91.18M
1W Leistung:
-5.59%
1M Leistung:
-5.70%
6M Leistung:
-28.33%
1J Leistung:
+33.19%
1-Tages-Spanne:
$15.88
$16.69
1-Wochen-Bereich:
$15.43
$17.22
52-Wochen-Spanne:
$11.68
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
15.89 | 1.66B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term? - Stocktwits
SRPT Looks 87.5% Undervalued on GF Value™ - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chaper - Fierce Pharma
Sarepta Names Former AbbVie Executive Michael Severino New CEO - Bloomberg
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
Sarepta names Michael Severino, former Tessera CEO, as new chief executive - STAT
Cambridge biotech taps external executive to lead after Elevidys controversy - The Business Journals
Sarepta Therapeutics Appoints Michael Severino as CEO - TipRanks
Sarepta names Michael Severino as new CEO, Ingram retires - Investing.com
Sarepta Therapeutics Inc (SRPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why is Sarepta Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Sarepta Therapeutics (SRPT) Appoints New CEO, Shares Surge 7% - GuruFocus
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire
How (SRPT) Movements Inform Risk Allocation Models - Stock Traders Daily
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
SRPT|Sarepta Therapeutics Inc|Price:15.680|Chg%:-0.200 - TradingKey
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Stocktwits
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Sarepta Therapeutics Market Sentiment - Benzinga España
Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com
Sarepta Therapeutics, Inc. Revenue Breakdown – NASDAQ:SRPT - TradingView
Sarepta Therapeutics Inc (SRPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sarepta Therapeutics stock steadies as investors weigh Elevidys expansion and revenue trajectory - Ad-hoc-news.de
SRPT: Sarepta Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Finviz
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Moomoo
Sarepta Therapeutics Stock Short Interest Rises to 32.62% - Quiver Quantitative
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 28.77% Potential Upside for Investors - DirectorsTalk Interviews
Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) - Supply Chain Digital
Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53? - Sahm
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued? - Yahoo Finance
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Yahoo Finance
Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape - DirectorsTalk Interviews
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):